We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App

Molbio Exhibits Its Novel POC Molecular Platform and Truenat Range of Tests at MEDICA 2021

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: Truelab Real Time Quantitative micro PCR System (Photo courtesy of Molbio Diagnostics)
Image: Truelab Real Time Quantitative micro PCR System (Photo courtesy of Molbio Diagnostics)

Molbio Diagnostics (Goa, India) exhibited its novel POC Truelab molecular platform and Truenat range of tests at MEDICA 2021, the leading international trade fair for the medical sector.

Molbio presented its fully automatic Truelab real time quantitative micro PCR system with a sample to results time of less than one hour. Among the Truelab systems presented at the event was the fully automatic Truelab Uno Dx real time quantitative micro PCR analyzer with a three wavelength system that performs 10-12 tests in eight hours. Molbio also highlighted the fully automatic Truelab Duo real time quantitative micro PCR analyzer with a two channel-three wavelength system that performs 20-24 tests in eight hours, alongside the fully automatic Truelab Quattro real time quantitative micro PCR analyzer with four channel-three wavelength system that performs 40-48 tests in eight hours. Molbio's Truelab also fits in a suitcase that can be transported easily anywhere and used by anyone. The platform can test over 30 diseases with a sample-to-result time of less than an hour, and the results can be transmitted instantly to any place via the IoT enabled platform.

Additionally, Molbio presented its Truenat range of disease-specific real time micro PCR tests at MEDICA 2021. The micro PCR chips are pre-loaded, ready-to-use and disposable. They are disease-specific and can be run on the Truelab Uno Dx/Duo/Quattro to get quantitative real-time PCR results. Among its wide range of Truenat real time micro PCR tests highlighted at the event was Truenat COVID-19, a chip-based RT PCR test for the semi quantitative detection of SARS CoV-2 RNA in human oropharyngeal and nasopharyngeal swab specimen. Molbio also showcased its WHO-endorsed Truenat MTB test for the quantitative detection and diagnosis of Mycobacterium tuberculosis (MTB) in human pulmonary and EPTB specimens that aids in the diagnosis of infection with MTB.

Related Links:
Molbio Diagnostics 

Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
3-Part Diff Hematology Analyzer
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
Automated R-AST Solution
Radian BC

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.